API | selumetinib

selumetinib (Koselugo) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Selumetinib (INN), sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.OS(=O)(=O)O
InChIKey: GRKFGZYYYYISDX-UHFFFAOYSA-N
Mol. Mass: 555.77
ALogP: 3.53 Partition coefficient
ChEMBL Molecules:

selumetinib sulfate

selumetinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Dual specificity mitogen-activated protein kinase kinase 1 (Homo sapiens) ^UniProt
- Dual specificity mitogen-activated protein kinase kinase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$55.1687 - $181.4760

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (94)

Research & Development (94)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (64)

Approved Indications (1)

Neurofibromatosis 1

Experimental Indications - Clinical Trial Phases 1-4 (64)

Adenocarcinoma (Phase 2)

Astrocytoma (Phase 3)

Bile Duct Neoplasms (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 2)

Esophageal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 1/Phase 2)

General Surgery (Phase 2)

Genes, Neurofibromatosis 1 (Phase 1/Phase 2)

Glioma (Phase 3)

Hamartoma (Phase 2)

Healthy Volunteers (Phase 1)

Heredodegenerative Disorders, Nervous System (Phase 2)

Kidney Neoplasms (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 3)

Meningioma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Nerve Tissue (Phase 2)

Neuroblastoma (Phase 2)

Neurofibroma (Phase 3)

Neurofibroma, Plexiform (Phase 2)

Neurofibromatosis 1 (Phase 3)

Neurofibromatosis 2 (Phase 2)

Neurofibrosarcoma (Phase 2)

Neuroma, Acoustic (Phase 2)

Optic Nerve Glioma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 1)

ras Proteins (Phase 2)

Rectal Neoplasms (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 2)

Thoracic Neoplasms (Phase 2)

Thymoma (Phase 2)

Thyroid Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 118
# of Trial Organizations: 94

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue